The U.S. Food and Drug Administration has approved an Abbreviated New Drug Application (ANDA) numbered ANDA085911 for an oral tablet containing 5 mg oxycodone hydrochloride and 500 mg acetaminophen, marketed under the brand name Oxycodone 5/APAP 500.
The product, submitted by Bristol Myers Squibb, received an approval status (AP) on October 25, 1977. FDA records indicate the marketing status is listed as discontinued.
Regulatory UpdatesSep 19, 2026•1 min read
FDA Approves ANDA085911 for Oxycodone 5/APAP 500 Oral Tablet
FDA approved ANDA085911 for an oral tablet containing 5 mg oxycodone and 500 mg acetaminophen, submitted by Bristol Myers Squibb; the product is listed as discontinued.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating